SCHEMBL21244046

SCHEMBL21244046

Cc1ccc(S(=O)(=O)Nc2cncnc2N2CCN(c3ccc(Cl)cc3F)CC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.49
HTT P42858 3/20 0.49
KMT2A Q03164 5/20 0.47
ALDH1A1 P00352 4/20 0.47
MEN1 O00255 3/20 0.47
LMNA P02545 4/20 0.42
TDP1 Q9NUW8 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TP53 P04637 2/20 0.42
CCR9 P51686 3/20 0.41
GAA P10253 2/20 0.41
SCN9A Q15858 1/20 0.40
PIK3CA P42336 1/20 0.40
KDM4E B2RXH2 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
KMO O15229 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21244035 0.86 MAPT (0.52) MAPTHTTKMT2AALDH1A1MEN1
SCHEMBL21244030 0.81 MAPT (0.55) MAPTHTTKMT2AALDH1A1MEN1
SCHEMBL21261305 0.74 CYP3A4 (0.37) MAPTHTTKMT2AALDH1A1MEN1
SCHEMBL21261304 0.74 CYP3A4 (0.43) L3MBTL1
SCHEMBL21244039 0.73 MAPT (0.46) MAPTHTTKMT2AALDH1A1MEN1
SCHEMBL21261303 0.73 POLB (0.43) MAPTHTTALDH1A1LMNATDP1
SCHEMBL21244042 0.71 ALDH1A1 (0.52) MAPTHTTKMT2AALDH1A1MEN1
SCHEMBL21244051 0.71 MCOLN3 (0.55) MAPTKMT2AALDH1A1MEN1LMNA
SCHEMBL21244034 0.69 L3MBTL1 (0.53) MAPTHTTKMT2AALDH1A1MEN1
SCHEMBL21244038 0.69 ALDH1A1 (0.54) MAPTHTTKMT2AALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10851084-B2 Piperazine derivatives as TRPML modulators Lysoway Therapeutics, Inc. (US) 2020-12-01 US claimed
US-20190248764-A1 PIPERAZINE DERIVATIVES AS TRPML MODULATORS CalyGene Biotechnolgy, Inc. (US) 2019-08-15 US claimed
US-10851084-B2 Piperazine derivatives as TRPML modulators Lysoway Therapeutics, Inc. (US) 2020-12-01 US disclosed
US-10851084-B2 Piperazine derivatives as TRPML modulators Lysoway Therapeutics, Inc. (US) 2020-12-01 US disclosed
US-20190248764-A1 PIPERAZINE DERIVATIVES AS TRPML MODULATORS CalyGene Biotechnolgy, Inc. (US) 2019-08-15 US disclosed
US-20190248764-A1 PIPERAZINE DERIVATIVES AS TRPML MODULATORS CalyGene Biotechnolgy, Inc. (US) 2019-08-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10851084-B2 Piperazine derivatives as TRPML modulators TRPM5, TRPM2, TRPM4 MAPT 577/4885HTT 531/4885KMT2A 2449/4885
US-20190248764-A1 PIPERAZINE DERIVATIVES AS TRPML MODULATORS TRPM5, TRPM2, TRPM4 MAPT 577/4885HTT 531/4885KMT2A 2449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.